Public record

Glucagon: the public record

2 tables from US federal sources. Latest data date: Nov 11, 2026.

Each table is computed from the named federal dataset as of its data date; the method is under each one.

Label

FDA label facts for glucagon

The FDA label read for glucagon (Gvoke HypoPen 0.5 mg Auto-Injector, application NDA212097) was last revised on 2026-09-30. It carries no boxed warning. Of the 4 population sections checked, 4 are present: pregnancy, lactation, pediatric use, geriatric use.

FDA label facts for glucagon: the figures
MeasureValueNote
Label revision date2026-09-30
Label readGvoke HypoPen 0.5 mg Auto-InjectorNDA212097, brand-name application
Boxed warningNo
Pregnancy sectionPresent
Lactation sectionPresent
Pediatric use sectionPresent
Geriatric use sectionPresent

Source: FDA drug label via openFDA, viewable on NIH DailyMed, data as of Nov 11, 2026

How this was calculated

Selected the most recently revised prescription label for this single ingredient from an original manufacturer, preferring a brand-name application. Checked which sections exist and quoted headings and sentences exactly as printed.

Scope: One label: the newest prescription label for single-ingredient glucagon from an original manufacturer

Read from one label. Labels for other brands, strengths or forms of the same ingredient can differ. A missing section heading does not mean there is no guidance. Read the full label before relying on it.

Download the data (CSV)

Medicare Part D

Medicare Part D spending on glucagon

Medicare Part D spending on glucagon products was $112.8M in 2024 across 242,348 claims, compared with $103.4M in 2023 (+9.0%). Average spending per claim was $465, before rebates.

Medicare Part D spending on glucagon: the figures
MeasureValueNote
Total spending, 2024$112.8M
Total spending, 2023$103.4M
Change in spending, 2023 to 2024+9.0%
Claims (prescription fills), 2024242,348
Average spending per claim, 2024$465
Gvoke Hypopen 2-Pack: spending, 2024$48.3M73,745 claims
Baqsimi: spending, 2024$21.5M43,157 claims
Glucagon Emergency Kit: spending, 2024$19.0M69,133 claims

Source: CMS, Medicare Part D Spending by Drug, data as of 2024

How this was calculated

Summed total spending and claims over every brand and generic row with this generic name in the CMS file, using the Overall manufacturer rows. Combination products excluded. Average per claim is spending divided by claims.

Scope: Every single-ingredient glucagon product in Part D (Gvoke Hypopen 2-Pack, Baqsimi, Glucagon Emergency Kit), 2024.

Gross drug cost before manufacturer rebates, so net cost is lower. Part D excludes some uses by law (for example erectile dysfunction, weight loss and hair growth), so claims reflect covered uses only. Compounded products are not included.

Download the data (CSV)

Articles on Glucagon